WaveMan
WaveMan · Company
CTNM · Contineum Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CTNM Contineum Therapeutics (CTNM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001855175
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
62
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $101.4K priced

What the filings say about CTNM

Insiders, 180 days
-$1.2M net sold
3 sellers · 8% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$438.5K
5 notices

Contineum Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Contineum Therapeutics, Inc. insiders sold a net $1.2M of stock across 34 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Stengone Carmine N.
CEO and President
SELL
2026-09-08 SEC
2,500
$41.1K
-46.2%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 3, 2026.
  • The trade is 14.5% of the 17,217 shares held after it.
  • No other insider sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Stengone Carmine N. sold about $41.1K of CTNM under a 10b5-1 plan on Sep 8, 2026; 62 funds added in the latest 13F quarter.
Stengone Carmine N.
CEO and President
SELL
2026-08-03 SEC
2,500
$40.0K
-48.8%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jul 8, 2026.
  • The trade is 14.5% of the 17,217 shares held after it.
  • 1 other insider sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Stengone Carmine N. sold about $40.0K of CTNM on Aug 3, 2026; 1 other insider sold within 30 days and 62 funds added in the latest 13F quarter.
Lorrain Daniel S.
Chief Scientific Officer
SELL
2026-07-10 SECtraded 2026-07-09
25
$400
-44.3%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Jul 8, 2026.
  • The trade is 0.0% of the 135,202 shares held after it.
  • 2 other insiders sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Lorrain Daniel S. sold about $400 of CTNM on Jul 9, 2026; 2 other insiders sold within 30 days and 62 funds added in the latest 13F quarter.
Lorrain Daniel S.
Chief Scientific Officer
SELL
2026-07-10 SECtraded 2026-07-08
1,015
$16.2K
-44.3%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Jul 1, 2026.
  • The trade is 0.8% of the 135,202 shares held after it.
  • 2 other insiders sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Lorrain Daniel S. sold about $16.2K of CTNM on Jul 8, 2026; 2 other insiders sold within 30 days and 62 funds added in the latest 13F quarter.
Stengone Carmine N.
CEO and President
SELL
2026-07-08 SEC
2,500
$40.0K
-47.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 30, 2026.
  • The trade is 14.5% of the 17,217 shares held after it.
  • 2 other insiders sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Stengone Carmine N. sold about $40.0K of CTNM on Jul 8, 2026; 2 other insiders sold within 30 days and 62 funds added in the latest 13F quarter.
34 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 29 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.2M over 180 days
-$81.2K over 90 days
below 64% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
62 funds bought in last quarter
more than 52% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.2% of the float short (float per yahoo 2026-10-27) · 2.2 days to cover · settled 2026-10-15
more than 87% of Pharma & Biotech
What changed in the last 30 days
Oct 1Officer Daniel Lorrain filed to sell $56.0K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch CTNM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-26.8%12M
-36%-5%+27%+58%2025-102025-122026-022026-042026-062026-082026-10 2026-06-30 · Lorrain Daniel S. sold $462.3K2026-06-30 · Watkins Tim sold $173.6K2026-06-30 · Stengone Carmine N. sold $160.1K2026-07-01 · Lorrain Daniel S. sold $91.7K2026-02-24 · Stengone Carmine N. sold $70.5K2026-02-24 · Lorrain Daniel S. sold $68.9K2026-03-02 · Lorrain Daniel S. sold $62.6K2026-02-25 · Lorrain Daniel S. sold $61.2K2026-04-06 · Lorrain Daniel S. sold $56.0K2026-06-01 · Lorrain Daniel S. sold $54.9K2026-03-02 · Watkins Tim sold $54.2K2025-12-23 · Lorrain Daniel S. sold $51.0K2026-05-01 · Lorrain Daniel S. sold $50.5K2026-02-03 · Lorrain Daniel S. sold $44.5K2025-12-29 · Watkins Tim sold $43.5K2026-02-25 · Stengone Carmine N. sold $43.3K2026-09-08 · Stengone Carmine N. sold $41.1K2026-07-01 · Lorrain Daniel S. sold $40.6K2026-08-03 · Stengone Carmine N. sold $40.0K2026-07-08 · Stengone Carmine N. sold $40.0K2026-01-28 · Watkins Tim sold $39.5K2026-01-05 · Lorrain Daniel S. sold $38.0K2026-02-03 · Lorrain Daniel S. sold $17.8K2026-07-08 · Lorrain Daniel S. sold $16.2K2026-01-28 · Watkins Tim sold $11.7K2026-02-11 · Stengone Carmine N. sold $6.4K2026-02-11 · Lorrain Daniel S. sold $6.4K2026-01-05 · Lorrain Daniel S. sold $5.6K2026-05-01 · Lorrain Daniel S. sold $4.2K2026-02-19 · Lorrain Daniel S. sold $1.6K2026-07-09 · Lorrain Daniel S. sold $4002026-10-01 · Daniel Lorrain filed to sell $56.0K2026-09-08 · CARMINE STENGONE filed to sell $41.8K2026-09-01 · Daniel Lorrain filed to sell $154.6K2026-08-03 · Daniel Lorrain filed to sell $147.5K2026-08-03 · CARMINE STENGONE filed to sell $38.7K2026-07-08 · CARMINE STENGONE filed to sell $36.4K2026-07-01 · Daniel Lorrain filed to sell $156.0K2026-06-30 · TIMOTHY WATKINS filed to sell $162.5K2026-06-30 · CARMINE STENGONE filed to sell $150.0K2026-06-30 · Daniel Lorrain filed to sell $432.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CTNM: institutional holders (13F)

13F holdings, latest reported quarter
MONTANOVA CAPITAL, LLC
2,841,334 sh
$46.6M
Jupiter Topco LLC
2,734,836 sh
$44.8M
BlackRock, Inc.
2,064,345 sh
$33.8M
JOHNSON & JOHNSON
1,979,173 sh
$32.4M
FRANKLIN RESOURCES INC
1,839,227 sh
$30.1M

Congress trades in CTNM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CTNM planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Daniel Lorrain
Filed 2026-10-01
$56.0K
CARMINE STENGONE
Filed 2026-09-08
$41.8K
Daniel Lorrain
Filed 2026-09-01
$154.6K
Daniel Lorrain
Filed 2026-08-03
$147.5K
CARMINE STENGONE
Filed 2026-08-03
$38.7K

CTNM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Franklin Biotechnology Discovery Fund
$5.1M position · as of 2026-07-31
0.4%
Franklin Biotechnology Discovery Fund
$4.6M position · as of 2026-07-31
0.4%
Ultra-Small Company Fund
$366.8K position · as of 2026-06-30
0.4%
Ultra-Small Company Market Fund
$440.9K position · as of 2026-06-30
0.3%
Fidelity Small Cap Stock Fund
$2.7M position · as of 2026-07-31
0.2%
Fidelity Small Cap Stock K6 Fund
$41.8K position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
0 active
1
Phase 2
1 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.2M sold by insiders over 180 days, 62 funds added last quarter, $438.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CTNM financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$53.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-28.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-26.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-31.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
-28.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenuen/a$0$50.0M
Operating income-$68.1M-$50.9M$16.1M
Net income-$60.0M-$42.3M$22.7M
EPS (diluted)-2.17-2.180.08
Operating cash flow-$55.3M-$32.8M$19.3M
Cash$75.6M$21.9M$15.5M
SEC XBRL, fiscal years, as known on 2026-10-28

CTNM Stock Sonar score 5/7 axes

Find similar shapesCompare

CTNM ranks highest on profitability (66th percentile) and risk and compliance (57th), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
66
Inputs
  • Return on equity-28.0% · 68 pct, sector of 545
  • Return on assets-26.6% · 63 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-31.6% · 66 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
17
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.1M · 34 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
52
Inputs
  • Funds adding, latest quarter62 · 52 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
57
Inputs
  • Short interest, % of float+11.1% · 36 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.1% · 78 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CTNM filings, in plain words

Are Contineum Therapeutics insiders buying or selling CTNM?

In the 180 days to 2026-10-28, Contineum Therapeutics insiders were net sellers, a net $1.2M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of CTNM?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $438.5K of stock; the latest, by Daniel Lorrain, was filed 2026-10-01.

Read the full summary

In the 180 days to 2026-10-28, Contineum Therapeutics insiders were net sellers of CTNM, a net $1.2M across purchases and sales reported on Form 4 by 3 sellers. 8% of the 13 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $438.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies